PBYI - Puma Biotechnology, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Los Angeles,
United States
Type: Equity
PBYI price evolution
PBYI
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $67.15 | $76.75 | $84.58 | $81.8 |
| Short term investments | $29.68 | $30.41 | $11.35 | $3.23 |
| Net receivables | $28.11 | $24.58 | $47.84 | $28.97 |
| Inventory | $9.05 | $7.1 | $7.08 | $5.68 |
| Total current assets | $137.72 | $143.03 | $156.19 | $125.35 |
| Long term investments | $2.09 | $2.09 | $2.09 | $2.59 |
| Property, plant & equipment | $6.91 | $7.78 | $8.65 | $9.45 |
| Goodwill & intangible assets | $56 | $58.44 | $60.87 | $63.3 |
| Total noncurrent assets | $67.28 | $71.12 | $74.34 | $78.25 |
| Total investments | $31.77 | $32.5 | $13.45 | $5.82 |
| Total assets | $205 | $214.15 | $230.53 | $203.6 |
| Current liabilities | ||||
| Accounts payable | $13.5 | $8.96 | $6.89 | $5.06 |
| Deferred revenue | ||||
| Short long term debt | $50.49 | $50.31 | $38.8 | $27.29 |
| Total current liabilities | $104.3 | $98.19 | $99.38 | $67.36 |
| Long term debt | $48.1 | $60.43 | $72.69 | $84.93 |
| Total noncurrent liabilities | $52.2 | $64.98 | $77.7 | $97.5 |
| Total debt | $98.59 | $110.73 | $111.49 | $112.22 |
| Total liabilities | $156.49 | $163.17 | $177.09 | $164.86 |
| Shareholders' equity | ||||
| Retained earnings | -$1354.51 | -$1349.98 | -$1345.16 | -$1357.43 |
| Other shareholder equity | -$0.03 | -$0.03 | -$0 | -$0 |
| Total shareholder equity | $48.51 | $50.98 | $53.44 | $38.74 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $84.58 | $76.2 | $71.98 | $94.14 |
| Short term investments | $11.35 | $4.87 | $18.98 | $8.1 |
| Net receivables | $47.84 | $42.27 | $32.53 | $25.54 |
| Inventory | $7.08 | $4.53 | $7.11 | $3.45 |
| Total current assets | $156.19 | $134.28 | $140.02 | $146.14 |
| Long term investments | $2.09 | $2.59 | $3.31 | $3.31 |
| Property, plant & equipment | $8.65 | $12.51 | $15.77 | $18.89 |
| Goodwill & intangible assets | $60.87 | $70.61 | $66.13 | $74.14 |
| Total noncurrent assets | $74.34 | $87.78 | $86.56 | $98.08 |
| Total investments | $13.45 | $7.46 | $22.29 | $11.41 |
| Total assets | $230.53 | $222.06 | $226.59 | $244.22 |
| Current liabilities | ||||
| Accounts payable | $6.89 | $6.44 | $11.17 | $12.08 |
| Deferred revenue | ||||
| Short long term debt | $38.8 | $4.14 | $3.57 | $17.38 |
| Total current liabilities | $99.38 | $77.48 | $109.59 | $114.25 |
| Long term debt | $72.69 | $98.31 | $113.07 | $103.57 |
| Total noncurrent liabilities | $77.7 | $122.97 | $119.44 | $135.92 |
| Total debt | $111.49 | $114.28 | $116.64 | $120.95 |
| Total liabilities | $177.09 | $200.45 | $229.03 | $250.17 |
| Shareholders' equity | ||||
| Retained earnings | -$1345.16 | -$1366.76 | -$1366.76 | -$1337.63 |
| Other shareholder equity | -$0 | -$0 | ||
| Total shareholder equity | $53.44 | $21.61 | -$2.45 | -$5.95 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $47.08 | $43.77 | $72.18 | |
| Cost of revenue | $10.66 | $10.73 | $24.32 | |
| Gross Profit | $36.42 | $33.04 | $47.85 | |
| Operating activities | ||||
| Research & development | $13.63 | $13.59 | $12.87 | |
| Selling, general & administrative | $24.97 | $21.75 | $20.18 | |
| Total operating expenses | $38.6 | $35.34 | $33.06 | |
| Operating income | -$2.18 | -$2.3 | $14.8 | |
| Income from continuing operations | ||||
| EBIT | -$0.78 | -$1.24 | $16.16 | |
| Income tax expense | $0.38 | $0.22 | $0.54 | |
| Interest expense | $3.37 | $3.36 | $3.35 | |
| Net income | ||||
| Net income | -$4.53 | -$4.82 | $12.27 | |
| Income (for common shares) | -$4.53 | -$4.82 | $12.27 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $235.64 | $228.03 | $253.16 | $225.11 |
| Cost of revenue | $62.68 | $55.09 | $63.7 | $39.37 |
| Gross Profit | $172.96 | $172.94 | $189.45 | $185.74 |
| Operating activities | ||||
| Research & development | $50.38 | $52.24 | $71.87 | $97.65 |
| Selling, general & administrative | $89.93 | $89.98 | $116.29 | $118.49 |
| Total operating expenses | $140.31 | $149.22 | $188.16 | $216.14 |
| Operating income | $32.64 | $23.72 | $1.29 | -$30.4 |
| Income from continuing operations | ||||
| EBIT | $36 | $12.05 | -$15.99 | -$45.74 |
| Income tax expense | $1.08 | $0.46 | $0.32 | $0.21 |
| Interest expense | $13.33 | $11.59 | $12.81 | $14.05 |
| Net income | ||||
| Net income | $21.59 | $0 | -$29.13 | -$59.99 |
| Income (for common shares) | $21.59 | $0 | -$29.13 | -$59.99 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$4.53 | -$4.82 | $12.27 | $5.8 |
| Operating activities | ||||
| Depreciation | $2.91 | $2.9 | $2.89 | $2.88 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.06 | $2.38 | $2.43 | $2.54 |
| Total cash flows from operations | $1.03 | $11.25 | $10.46 | $10.62 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.04 | -$0.03 | |
| Investments | $0.72 | -$19.08 | -$8.13 | $11.21 |
| Total cash flows from investing | $0.7 | -$19.08 | -$8.17 | $11.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$11.11 | |||
| Total cash flows from financing | -$11.33 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.6 | -$7.83 | $2.29 | $21.79 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $21.59 | $0 | -$29.13 | -$59.99 |
| Operating activities | ||||
| Depreciation | $11.52 | $8.92 | $10.6 | $10.03 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.25 | $11.83 | $32.63 | $36.58 |
| Total cash flows from operations | $27.01 | -$15.83 | $20.65 | $0.77 |
| Investing activities | ||||
| Capital expenditures | -$0.14 | -$0.05 | ||
| Investments | -$6.49 | $14.1 | -$10.88 | $43.45 |
| Total cash flows from investing | -$19.13 | $7.1 | -$10.88 | $23.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $12.22 | $0.07 | ||
| Net borrowings | -$11.93 | |||
| Total cash flows from financing | $12.22 | -$31.93 | $0.07 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.88 | $3.5 | -$22.16 | $24.24 |
News
Fundamentals
| Market cap | $140.53M |
|---|---|
| Enterprise value | $171.97M |
| Shares outstanding | 48.46M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 2.90 |
| Book/Share | 1.00 |
| Cash/Share | 1.39 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 3.31 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.32 |
| Quick ratio | 1.23 |